Rituximab Biosimilar clinical trials

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

This study compares two treatments for a fast-growing blood cancer called diffuse large B-cell lymphoma (DLBCL), specifically a type called GCB DLBCL. Researchers want to see if a new drug, zilovertamab vedotin, when combined with standard therapy, works better than another combination in shrinking the cancer.